Regional Fish Institute Ltd. in Japan is now accepting orders on a crowdfunding site for genetically manipulated farmed red sea bream that boasts 1.2 times thicker flesh than ordinary farmed ones.
Sales are initially restricted to 190 customers with deliveries expected to start in October. The production process is explained in detail with each purchase.
Kyoto University and Kindai University developed the fleshier fish variant by rendering a gene called myostatin that controls muscle growth.
The Regional Fish Institute, a biotech enterprise affiliated with Kyoto University, registered the commercialization of its “genome-edited food” with the government on Sept. 17.
On the same day, the health ministry declared that no safety examinations were required.
Genome editing, which aims to destroy or introduce particular genes, is also applied for increasing harvest yields in rice and other plant varieties.
As no foreign genes from other species were introduced into genome-processed items, as with genetic recombination, no safety checks were necessary.
This method is essentially the same as traditional selective breeding methods to create improved varieties.
The institute's sea bream is the first genome-edited animal product to be marketed in Japan.


India Budget 2026: Modi Government Eyes Reforms Amid Global Uncertainty and Fiscal Pressures
China Factory Activity Slips in January as Weak Demand Weighs on Growth Outlook
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Asian Stocks Waver as Trump Signals Fed Pick, Shutdown Deal and Tech Earnings Stir Markets
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern
China Manufacturing PMI Slips Into Contraction in January as Weak Demand Pressures Economy
Gold and Silver Prices Plunge as Trump Taps Kevin Warsh for Fed Chair
Canada’s Trade Deficit Jumps in November as Exports Slide and Firms Diversify Away From U.S.
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Starmer’s China Visit Highlights Western Balancing Act Amid U.S.-China Rivalry 



